title: [Diabetic retinopathy: new therapeutic possibilities].
abstract: Diabetic retinopathy affects an increasing number of persons, about 4 millions in Europe, a number that will probably double until 2030. If we consider that 25-30% of patients are affected by diabetic retinopathy, an ophthalmologic screening and early therapy will allow a better visual prognosis and avoid severe ocular complications such as diabetic macular edema and proliferative diabetic retinopathy. A summary of current ophthalmologic literature was performed and was focused on the role of anti-VEGF (vascular endothelial growth factor) therapies and intraocular drug delivery of corticosteroids in a pathology that was recently classified in inflammatory pathologies.
authors: Yan
authors: Y
authors: Guex-Crosier
authors: Francine
authors: F
authors: Behar-Cohen
mesh_terms: D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D042461:Vascular Endothelial Growth Factor A